PHARMACY

FDA approves Glenmark’s Emend generic

BY David Salazar

SILVER SPRING, Md. — The Food and Drug Administration has approved Glenmark Pharmaceuticals’ generic Emend (aprepitant) capsules. The drug is indicated to prevent nausea and vomiting in patients undergoing chemotherapy.

Glenmark’s generic will be available in 40-, 80- and 125-mg dosage strength capsules. The product had branded and generic U.S. sales of approximately $64.9 million for the 12 months ended August 2017, according to QuintilesIMS data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

CVS Health, Epic partner on insights to bring care team together

BY David Salazar

WOONSOCKET, R.I. — CVS Health’s latest partnership is looking to make it easier for prescribers to see lower-cost alternatives through analytics and data sharing. The company is working Epic, whose Health Planet population health and analytics platform creates insights around medication dispensing patterns and adherence behaviors.

“This collaboration with Epic will enable us to continue to drive leading edge technology innovation beyond the pharmacy to the full health care system," CVS health chief information officer Stephen Gold said. “Together, our two companies will also examine opportunities to streamline and improve data sharing and linkages across the health care system to enhance communication and connectivity among patients, their physicians, the pharmacy and health insurers.”

The companies said the partnership would help improve decision-making abilities for patients and their care teams — including physicians, pharmacists and payers. Real-time benefit information and point-of-prescribing prior authorization will be provided in an effort to simplify access to necessary medications for patients and ensure that their prescribers are aware of a prescription’s formulary status and less expensive alternatives.

“At CVS Health we recognize that EHRs offer healthcare providers easier and more comprehensive access to their patients' information than ever before,” CVS Health chief medical officer Dr. Troyen Brennan said. “This new relationship will help us further expand how we work with Epic and providers on their EHR system to develop meaningful tools and programs that will ultimately help us take even better care of the patients we support.”

The partnership will allow CVS Health and Epic to explore improved prescribing decisions through the development of a comprehensive clinical database to enhance medication counseling and help optimize medication selection for CVS Health patients. The companies also will look into a shared care plan for pharmacists, which would improve pharmacist access to clinical information and allow contribution to the care plan. The collaboration also will explore digital front-store capabilities to enable over-the-counter and durable medical equipment to be included in a patient’s HER.

"CVS Health is one of the leaders in using data to dissolve domain silos, while offering new sources of intelligence and expertise that can better inform care delivery, reduce administrative overhead, and lower costs for patients,” Epic VP Population Health Alan Hutchison said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Amgen CEO named PhRMA board chairman-elect

BY David Salazar

WASHINGTON — The Pharmaceutical Research and Manufacturers of America has new officers on its board of directors. The organization has named Amgen chairman and CEO Robert Bradway to the chairman-elect position, effective immediately, and named two more industry executives to the board.

In addition to Bradway, Sanofi CEO Olivier Brandicourt will become chairman-elect and Astellas Americas president James Robinson will become treasurer, effective Feb. 7, 2018. Bradway, who was formerly board treasurer, succeeds Johnson & Johnson EVP and worldwide chairman pharmaceuticals Joaquin Duato as chairman-elect.

“I am pleased to welcome Bob to the board as our chairman-elect,” PhRMA president and CEO Stephen Ubl said. “Our companies are developing therapies unimaginable just a decade ago, and these advances will help many patients with serious and debilitating diseases. Together, we will ensure this innovation continues by advancing a comprehensive set of market-based reforms that improve access and affordability for patients.”

Bradway has been with Amgen since 2006, serving as CEO since 2012 and chairman since 2013. He also is the chairman of the CEO Roundtable on Cancer and is a member of Boeing’s board of directors. Brandicourt has been CEO of Sanofi since April 2015, joining the company from his post at Bayer Healthcare as a member of the executive leadership team. Robinson has led Astellas Americas since April 2016, having previously led its pharmaceuticals commercial in the organization in the United States. He joined the company in 2005 as VP health systems. Previously, he work with Schering-Plough, which was acquired by Merck in 2009.

“Now, more than ever, PhRMA member companies are bringing forth an unprecedented series of medical innovations to support human health,” Bradway said.  Our innovations promise to not only improve and extend the lives of millions of patients, but also to positively bend the cost curve by decreasing the financial burden of serious diseases on society. I look forward to working together with stakeholders across the health care continuum to ensure a fertile environment for innovation and to encourage creative policy positions so that patients have access to the medicines they need.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?